S
COGT icon

SignatureFD’s Cogent Biosciences COGT Stock Holding History

SignatureFD’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.91K Sell
101
-17
-14% -$595 ﹤0.01% 2942
2026
Q1 		$4.54K Buy
118
+17
+17% +$628 ﹤0.01% 2810
2025
Q4 		$3.59K Hold
101
– – ﹤0.01% 2809
2025
Q3 		$1.45K Hold
101
– – ﹤0.01% 3018
2025
Q2 		$725 Sell
101
-110
-52% -$610 ﹤0.01% 3063
2025
Q1 		$1.26K Buy
211
+91
+76% +$713 ﹤0.01% 2992
2024
Q4 		$936 Hold
120
– – ﹤0.01% 3045
2024
Q3 		$1.3K Hold
120
– – ﹤0.01% 2945
2024
Q2 		$1.01K Hold
120
– – ﹤0.01% 2900
2024
Q1 		$806 Buy
120
+44
+58% +$272 ﹤0.01% 2974
2023
Q4 		$447 Buy
+76
New +$582 ﹤0.01% 2987
2023
Q1 		– Sell
-65
Closed -$751 – 3297
2022
Q4 		$751 Sell
65
-15
-19% -$186 ﹤0.01% 3028
2022
Q3 		$1K Buy
+80
New +$1.1K ﹤0.01% 2930

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SignatureFD's COGT Position: Q2 2026 in Review

SignatureFD reduced its Cogent Biosciences (COGT) stake by 14% in Q2 2026, selling an estimated $595 and leaving 101 shares worth $3.91K. The position accounts for ﹤0.01% of the portfolio, ranked #2942.

SignatureFD first reported a position in COGT in Q3 2022 and has held it in 13 quarters since. The position peaked at $4.54K in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • SignatureFD held 101 shares of Cogent Biosciences worth $3.91K as of Q2 2026.
  • SignatureFD sold 17 Cogent Biosciences shares in Q2 2026, an estimated $595.
  • Cogent Biosciences made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2942 holding.
  • SignatureFD first reported a position in Cogent Biosciences in Q3 2022 and has held it in 13 quarters since.
  • SignatureFD's Cogent Biosciences position peaked at $4.54K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.